Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of levosulpiride in healthy subjects

Neuroscience

Volumn 169, Issue 1, 2010, Pages 378-387

  Cho, H Y ^a   Yoo, H D ^b   Lee, Y B ^b  

^a Korea Food and Drug Administration   (South Korea)

^b Chonnam National University   (South Korea)

Author keywords

Blood brain barriers; Genotype; Haplotype; Knockout mice; P glycoprotein; SNP

Indexed keywords

ALANINE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; SERINE; SULPIRIDE; THREONINE;

ADULT; ALLELE; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; ENCEPHALE ISOLE; EXON; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; KOREA; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE DRUG DOSE; TIME; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER; WILD TYPE;

ADULT; ALLELES; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL AVAILABILITY; BRAIN CHEMISTRY; EXONS; GENE FREQUENCY; GENOTYPE; HUMANS; INTESTINAL ABSORPTION; MALE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOM ALLOCATION; REPUBLIC OF KOREA; SULPIRIDE; YOUNG ADULT;

EID: 77953812053     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.04.065     Document Type: Article

References (48)

1. Baluom M., Friedman M., Rubinstein A. Improved intestinal absorption of sulpiride in rats with synchronized oral delivery systems. J Control Release 2001, 70:139-147.
2. Bateman D.N. Pharmacokinetics and metabolism of the benzamides. Adv Biochem Psychopharmacol 1982, 35:143-162.
3. Bressolle F., Bres J., Blanchin M.D., Gomeni R. Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels. J Pharm Sci 1984, 73:1128-1136.
4. Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Schwab M., Schaeffeler E., Eichelbaum M., Brinkmann U., Roots I. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001, 69:169-174.
5. Catapano F., Maj M., Grimaldi F., Ventra C., Kemali D. Efficacy of low vshigh doses of levosulpiride on negative symptoms of schizophrenia. Pharmacopsychiatry 1992, 25:166.
6. Cho H.Y., Lee Y.B. Improvement and validation of a liquid chromatographic method for the determination of levosulpiride in human serum and urine. J Chromatogr B Analyt Technol Biomed Life Sci 2003, 796:243-251.
7. Chowbay B., Cumaraswamy S., Cheung Y.B., Zhou Q., Lee E.J.D. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003, 13:89-96.
8. Croop J.M., Raymond M., Haber D., Devault A., Arceci R.J., Gros P., Housman D.E. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 1989, 9:1346-1350.
9. Devault A., Gros P. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 1990, 10:1652-1663.
10. Distrutti E., Fiorucci S., Hauer S.K., Pensi M.O., Vanasia M., Morelli A. Effect of acute and chronic levosulpiride administration on gastric tone and perception in functional dyspepsia. Aliment Pharmacol Ther 2002, 16:613-622.
11. Excoffier L., Laval G., Schneider S. Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol Bioinform Online 2005, 1:47-50.
12. Gerlach J. New antipsychotics: classification, efficacy, and adverse effects. Schizophr Bull 1991, 17:289-309.
13. Haufroid V., Mourad M., Van Kerckhove V., Wawrzyniak J., De Meyer M., Eddour D.C., Malaise J., Lison D., Squifflet J.P., Wallemacq P. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004, 14:147-154.
14. Higgins C.F. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 1992, 8:67-113.
15. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmoller J., Johne A., Cascorbi I., Gerloff T., Roots I., Eichelbaum M., Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000, 97:3473-3478.
16. Hsu S.I., Lothstein L., Horwitz S.B. Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells. Evidence that distinct P-glycoprotein precursors are encoded by unique mdr genes. J Biol Chem 1989, 264:12053-12062.
17. Jenner P., Marsden C.D. Substituted benzamide drugs as selective neuroleptic agents. Neuropharmacology 1981, 20:1285-1293.
18. Johne A., Kopke K., Gerloff T., Mai I., Rietbrock S., Meisel C., Hoffmeyer S., Kerb R., Fromm M.F., Brinkmann U., Eichelbaum M., Brockmoller J., Cascorbi I., Roots I. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002, 72:584-594.
19. Kim R.B., Leake B.F., Choo E.F., Dresser G.K., Kubba S.V., Schwarz U.I., Taylor A., Xie H.G., McKinsey J., Zhou S., Lan L.B., Schuetz J.D., Schuetz E.G., Wilkinson G.R. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001, 70:189-199.
20. Kroetz D.L., Pauli-Magnus C., Hodges L.M., Huang C.C., Kawamoto M., Johns S.J., Stryke D., Ferrin T.E., DeYoung J., Taylor T., Carlson E.J., Herskowitz I., Giacomini K.M., Clark A.G. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003, 13:481-494.
21. Kuypers D.R., de Jonge H., Naesens M., Vanrenterghem Y. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet Genomics 2008, 18:861-868.
22. Lee C.G., Gottesman M.M., Cardarelli C.O., Ramachandra M., Jeang K.T., Ambudkar S.V., Pastan I., Dey S. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998, 37:3594-3601.
23. Leschziner G.D., Andrew T., Pirmohamed M., Johnson M.R. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 2007, 7:154-179.
24. Macdonald N., Gledhill A. Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans. Arch Toxicol 2007, 81:553-563.
25. Macphee I.A., Fredericks S., Tai T., Syrris P., Carter N.D., Johnston A., Goldberg L., Holt D.W. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002, 74:1486-1489.
26. Mai I., Perloff E.S., Bauer S., Goldammer M., Johne A., Filler G., Budde K., Roots I. MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol 2004, 58:548-553.
27. Marzolini C., Paus E., Buclin T., Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004, 75:13-33.
28. Mason B.L., Pariante C.M., Thomas S.A. A revised role for P-glycoprotein in the brain distribution of dexamethasone, cortisol, and corticosterone in wild-type and ABCB1A/B-deficient mice. Endocrinology 2008, 149:5244-5253.
29. Mauri M.C., Leva P., Coppola M.T., Altamura C.A. L-sulpiride in young and elderly negative schizophrenics: clinical and pharmacokinetic variables. Prog Neuropsychopharmacol Biol Psychiatry 1994, 18:355-356.
30. Min D.I., Ellingrod V.L. C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2002, 24:400-404.
31. Mizuno N., Morita E., Nishikata M., Shinkuma D., Yamanaka Y. Gastrointestinal absorption of sulpiride in rat. Arch Int Pharmacodyn Ther 1986, 283:30-38.
32. Morita N., Yasumori T., Nakayama K. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol 2003, 65:1843-1852.
33. Rossi F., Forgione A. Pharmacotoxicological aspects of levosulpiride. Pharmacol Res 1995, 31:81-94.
34. Sakaeda T., Nakamura T., Horinouchi M., Kakumoto M., Ohmoto N., Sakai T., Morita Y., Tamura T., Aoyama N., Hirai M., Kasuga M., Okumura K. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001, 18:1400-1404.
35. Schinkel A.H., Mayer U., Wagenaar E., Mol C.A., van Deemter L., Smit J.J., van der Valk M.A., Voordouw A.C., Spits H., van Tellingen O., Zijlmans J.M., Fibbe W.E., Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A 1997, 94:4028-4033.
36. Schinkel A.H., Mol C.A., Wagenaar E., van Deemter L., Smit J.J., Borst P. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 1995, 31A:1295-1298.
37. Shinkai T., De Luca V., Utsunomiya K., Sakata S., Inoue Y., Fukunaka Y., Hwang R., Ohmori O., Kennedy J.L., Nakamura J. Functional polymorphism of the human multidrug resistance gene (MDR1) and polydipsia-hyponatremia in schizophrenia. Neuromolecular Med 2008, 10:362-367.
38. Tada H., Tsuchiya N., Satoh S., Kagaya H., Li Z., Sato K., Miura M., Suzuki T., Kato T., Habuchi T. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc 2005, 37:1730-1732.
39. Tanabe M., Ieiri I., Nagata N., Inoue K., Ito S., Kanamori Y., Takahashi M., Kurata Y., Kigawa J., Higuchi S., Terakawa N., Otsubo K. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001, 297:1137-1143.
40. Tang K., Ngoi S.M., Gwee P.C., Chua J.M., Lee E.J., Chong S.S., Lee C.G. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002, 12:437-450.
41. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987, 84:7735-7738.
42. Uhr M., Tontsch A., Namendorf C., Ripke S., Lucae S., Ising M., Dose T., Ebinger M., Rosenhagen M., Kohli M., Kloiber S., Salyakina D., Bettecken T., Specht M., Putz B., Binder E.B., Muller-Myhsok B., Holsboer F. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008, 57:203-209.
43. Watanabe K., Sawano T., Endo T., Sakata M., Sato J. Studies on intestinal absorption of sulpiride (2): transepithelial transport of sulpiride across the human intestinal cell line Caco-2. Biol Pharm Bull 2002, 25:1345-1350.
44. Watanabe K., Sawano T., Jinriki T., Sato J. Studies on intestinal absorption of sulpiride (3): intestinal absorption of sulpiride in rats. Biol Pharm Bull 2004, 27:77-81.
45. Watanabe K., Sawano T., Terada K., Endo T., Sakata M., Sato J. Studies on intestinal absorption of sulpiride (1): carrier-mediated uptake of sulpiride in the human intestinal cell line Caco-2. Biol Pharm Bull 2002, 25:885-890.
46. Wiesel F.A., Alfredsson G., Ehrnebo M., Sedvall G. The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. Eur J Clin Pharmacol 1980, 17:385-391.
47. Yates C.R., Zhang W., Song P., Li S., Gaber A.O., Kotb M., Honaker M.R., Alloway R.R., Meibohm B. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003, 43:555-564.
48. Zhou S.F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008, 38:802-832.